ManagementWith Vyvgart established, argenx looks beyond its founder CEOThe Dutch biotech argenx has announced a planned leadership transition to be effective in May after its annual shareholder meeting. Tim Van Hauwermeiren, co-founder and long-time Chief Executive Officer, … more ➔
R&D collaborationsServier and Insilico sign an $888 million AI oncology discovery dealOn January 4, the French pharma group Servier and the AI drug discovery Insilico Medicine announced a collaboration worth up to $888 million. Insilico will receive up to $32 million from Servier for … more ➔
IQVIAObesityFDA approves globally first obesity pillFDA approves Novo Nordisk’s first oral GLP-1 pill Wegovy for obesity, offering an injection-free option and improving long-term treatment adherence. more ➔
White HouseUS Pharma PricesNine Big Pharma to cut US drug prices in Most-favoured Nations dealsNine pharma giants will cut US drug prices up to 90 % via TrumpRx and direct channels, following previous Pfizer and AstraZeneca MFN deals. more ➔
ClarivateUS Biosecure ActTrump Administration tables new version of Biosecure ActThe Trump administration has tabled a new Biosecure Act, prompting industry concern over oversight shift, regulatory uncertainty and need for stronger US biotech strategy. more ➔
H. Zell - wikipedia.orgagri-biotechEU committee approves New Plant Breeding (NGT) techniquesOn Friday, the EU committee of Permanent Representatives of EU Member States backed the deregulation of new genomic plant breeding techniques, easing regulation for NGT1 crops. more ➔
FDARegulatoryEgetis Therapeutics AB submits rolling NDA for tiratricolEgetis Therapeutics has submitted a rolling NDA for Tiratricol to treat rare MCT8 transporter deficiency. The application for priority review is based on positive ReTRIACt study results. more ➔
University of GenevaFinancingFoRx raises US$50m in Series A to advance PARG inhibitorSwiss cancer specialist FoRx Therapeutics AG has secured US$50m Series A to fund Phase I development of FORX-428, supporting IND, trial execution and clinical data readout by mid-2026. more ➔
MRM Health NVAntiinflammationBelgian microbiome player MRM Health initiates R&D partnership in cancer immunotherapyFollowing a €55m (US$64m) Series B financing in September, Ghent-based MRM Health today announced a strategic collaboration with the research group of Professor Emile Voest, Senior Group Leader at … more ➔
EC- press serviceEUBiopharmaceutical sector welcomes EU Biotech ActThe European Commission has unveiled the first part of its draft for a Biotech Act, focusing on health and medical biotechnology. The proposal has won strong support from industry stakeholders, who … more ➔
IQVIA
White House
Clarivate
H. Zell - wikipedia.org
FDA
University of Geneva
MRM Health NV
EC- press service